Drugs / MO-03
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07578025 | Nov 2026 → Jun 2028 expected | clear cell renal carcinoma | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07552181 | Sep 2026 → Sep 2035 expected | triple-negative breast carcinoma | Yuan Yuan | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MO-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07578025 ↗ |
| Modality | Other / unclassified | “Live biotherapeutic product” NCT07552181 ↗ |
| Route | Oral | “1 capsule taken orally twice daily” NCT07552181 ↗ |